Articles tagged with Small Molecules
Researchers developed an AI tool, AIMe, to predict and organize small molecule structures, covering over 100 million compounds. The tool, called DeepMS2Reasoner, uses neuro-symbolic AI to simulate molecule fragmentation, providing interpretable outputs and accelerating hypothesis generation.
A clinical trial of Ceperognastat, a novel O-linked N-acetylglucosaminidase inhibitor, found no significant slowing of Alzheimer's disease progression in early symptomatic patients. The study published in JAMA suggests that Ceperognastat may not be effective in treating this stage of the disease.
Researchers at NINN and SOKENDAI develop a new strategy for synthesizing three-dimensional macrocycles in a square shape, featuring acid responsiveness and recyclability. The method uses an imine bond to create the shape, respond to stimuli, and revert back.
The latest volume of SLAS Discovery highlights advances in 3D cell culture and novel technologies for drug discovery. Small molecule cytokine antagonists and a versatile ELISA for PPI inhibitor screening are among the key findings.
The companies are leveraging generative AI to develop innovative candidates for challenging neurological diseases, aiming to provide a broader range of therapeutic options. Insilico's Pharma.AI platform and Tenacia's expertise will continue to generate innovative solutions with strong translational potential.
Insilico Medicine and CMS announce multiple collaborations on AI-empowered drug discovery in central nervous system and autoimmune diseases. The partnerships aim to accelerate research, development, and translation of high-potential innovative therapies, leveraging complementary strengths across the entire value chain.
Insilico Medicine showcases its Pharma.AI platform's capabilities in generating biologics and analyzing data to accelerate drug discovery. The company's latest updates include improved Generative Biologics, Chemistry42/Nach01, and PandaOmics features.
A University of Houston chemist has received a nearly $2M grant to develop molecular blueprints for controlling how molecules change shape and reactivity upon absorbing light. This research could lead to breakthroughs in storing and using chemical energy, as well as designing materials that change when exposed to light.
Insilico Medicine will demonstrate how generative AI is accelerating therapeutic discovery, improving drug efficacy, and advancing personalized medicine. The company's pharma superintelligence platform aims to tackle challenging problems in modern science and medicine.
Insilico Medicine has released several AI-powered tools, including PandaOmics and Generative Biologics, to accelerate drug discovery. These platforms utilize machine learning and AI models to analyze large datasets and generate novel hypotheses.
Insilico Medicine's founder Alex Zhavoronkov, PhD, is named among 100 global leaders driving the future of artificial intelligence. The company has developed breakthrough solutions for novel target discovery and drug development using generative AI.
Researchers create peptide hydrogel that controls drug release, improving treatment adherence and efficacy for conditions like tuberculosis and diabetes. The SABER platform uses reversible chemical bonds to slow down drug release, offering a promising solution for precise delivery.
Researchers at Max-Planck-Institut für Kernphysik recreated a reaction under conditions similar to those in the early universe for the first time. They found that the rate of this reaction remains almost constant with decreasing temperature, contradicting previous predictions.
Linna An joins Rice University to develop protein-based biosensors for cancer detection, drug monitoring, and personalized diagnostics. Her work focuses on mapping the 'metabolism landscape' of cancer using synthetic proteins.
Researchers have determined the near-atomic-resolution structure of the human ATR–ATRIP complex, clarifying key features and interactions. The study identified novel binding modes for two clinical ATR inhibitors, VE-822 and RP-3500, providing insights into designing next-generation therapies.
Isowalsuranolide activates autophagy-dependent cell death by targeting TrxR1/2, leading to ROS-mediated lysosomal biogenesis and reduced cell growth. The study reveals the TrxR1/2-p53-TFEB/TFE3 axis as a key regulator of cellular homeostasis in cancer.
A study published in Cell suggests that the gut microbiome can play a key role in protecting against gastrointestinal (GI) diseases by breaking down certain plant compounds. The researchers found that specific intestinal microbes release beneficial small molecules that regulate inflammation and promote resistance to pathogens, such as ...
Eradivir's EV25 is a small molecule immunotherapy biotech company developing treatments for influenza. The Phase 2 challenge study will gather safety and efficacy data from healthy participants infected with influenza.
Researchers at the University of Missouri have identified a small molecule drug that targets a specific serotonin receptor, showing promise as a treatment for sarcopenia. The study suggests that this neurotherapeutic can improve muscle strength by activating motor neurons to fire more effectively.
A new study by Rice University and Vanderbilt University researchers found that combining focused ultrasound with the existing protein therapy TRAIL can significantly reduce tumor size and burden in prostate cancer models. The therapy works by amplifying the anticancer effects of TRAIL via Piezo1 activation, which triggers cell death.
Researchers have identified a small molecule that can successfully disable the virus' mechanisms, reducing viral particles by 1,000 times. The discovery could lead to effective preventative treatments and applications for human anti-viral drug development.
The Predictive Phenomics Initiative and the Exposome Moonshot aim to understand the impact of molecular signaling on organisms. Environmental factors, such as diet and lifestyle, can significantly affect biological processes, influencing traits like height, disease risk, and even eye color.
Researchers at U of T have developed a new platform called smol-seq that uses DNA sequencing to detect metabolites. This method enables the analysis of hundreds of metabolites simultaneously, making it faster and more precise than current methods.
A West Virginia University legal scholar argues that current laws favor biologic drugs with longer exclusivity periods, affecting their pricing. The scholar suggests reducing exclusivity for biologics to bring them in line with small-molecule drugs, which could lower drug costs.
The EPFL team has developed a deep-learning pipeline called MaSIF to design new proteins that interact with therapeutic targets. They have successfully designed novel protein binders that can recognize and bind to drug-protein complexes, offering potential applications in cell-based therapies and biosensors.
Researchers have developed a new geometric machine learning method called MaSIF, which enables the design of proteins that bind specifically to desired molecular structures. This approach accelerates precision drug development by allowing for precise dosing and control of biological drugs.
Researchers at U of T have created SIMPL2, a platform that simplifies detection and improves accuracy of protein-protein interactions. The tool enables the rapid identification of protein interactions, including weak ones, for targeted drug therapies.
Insilico Medicine has received its first clinical milestone payment of $10 million from Exelixis for XL309, a selective USP1 inhibitor discovered with the company's AI platform. The drug is being developed for advanced solid tumors and has shown efficacy in preclinical studies.
Researchers at University of Wisconsin-Madison develop a new method called Sensor-seq to identify small molecules in samples quickly and inexpensively. This can help detect pollutants and environmental toxins, improve first-response and emergency medicine, and enable at-home health monitoring.
Researchers have identified a form of Vitamin B6 bound to MR1 as a means of engaging tumour-reactive immune cells, suggesting that altered cellular metabolism/metabolite levels may distinguish cancer cells. Understanding the breadth of MR1-mediated immunity could illuminate routes for therapeutic intervention with broad utility.
EV25, a bispecific small molecule developed by Eradivir, acts faster than the current standard of care, eliminating detectable virus within 24 hours. It also recruits naturally occurring antibodies to fight the virus, reducing viral loads and protecting against lung damage.
A new oral medication, muvalaplin, has shown promising results in lowering lipoprotein(a) levels, a marker of cardiovascular risk. The study's findings suggest that muvalaplin may be a valuable treatment option for individuals with high lipoprotein(a) levels.
Plant roots use a silent molecular 'language' to direct fungi to attach, providing phosphates. Researchers discovered that strigolactone activates fungal genes associated with phosphate metabolism, leading to new strategies for cultivating hardier crops and combatting disease-causing fungi.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.
Scripps Research scientists have identified a crucial binding site on the protein FOXA1 that could pave the way for future cancer treatments. The team's findings mapped out how tiny drug-like chemical compounds interact with the protein, revealing a hidden lock that small molecules can bind to.
Researchers aim to develop small molecule drugs to target neuroinflammation in the brain, which contributes to cognitive decline. The goal is to slow or even cure Alzheimer's disease, offering a potential game-changer for the therapeutic landscape.
Researchers at Ohio State University have developed a novel method to strengthen polyvinyl chloride (PVC) products by permanently attaching chemical additives using electricity. This new approach can prevent microplastic degradation and improve the material's durability, making it more suitable for various applications.
A new study published in the journal JCI Insight found that male mice fed high-cholesterol diets have increased cardiovascular disease risk in their female offspring. The researchers used a novel method to study sperm small RNA and discovered altered molecules that affect gene expression in early embryonic stem cells.
A new study published in Microorganisms highlights the importance of small molecule drugs that target the unchanging parts of the SARS-CoV-2 virus. The research suggests that these stable targets could provide a consistent and reliable treatment option for COVID-19, even as vaccines are updated to address changing viral strains.
Researchers have developed a new method to increase speed and success rates in drug discovery by combining data from the Library of Integrated Network-based Cellular Signatures with targeted docking simulations. This approach can accelerate the drug research process, identifying potentially effective compounds more efficiently.
Researchers discovered a new small molecule, SR-18292, that increases fetal hemoglobin production and reduces sickled red blood cells in mice with sickle cell disease. The study suggests that combining SR-18292 with hydroxyurea could provide a vital new treatment option for patients who don't respond well to traditional treatments.
Researchers at the University of Illinois Chicago have developed a new dual-action antibiotic that targets two different cellular targets, making it nearly impossible for bacteria to evolve resistance. The antibiotic works by disrupting protein production and DNA structure, rendering random mutations ineffective.
Researchers at UNC School of Medicine have identified a small molecule that could potentially treat Angelman syndrome by 'turning on' the dormant paternally-inherited UBE3A gene copy. The compound, (S)-PHA533533, has shown excellent uptake in developing brains and bioavailability, making it a promising lead for gene therapy.
Researchers at Istituto Italiano di Tecnologia and EMBL unveiled how to modulate gene expression using small molecules. The study aims to develop new drugs specific to genetic mutations or alterations responsible for the onset of tumors or genetic diseases.
A new adapter molecule recruits a previously unknown E3 ligase for targeted protein degradation, expanding therapeutic options for cancer and rare diseases. The discovery offers advantages in development due to the molecule's smaller size and potential for tissue-specific application.
Researchers have developed a novel approach to convert native sugars into diverse classes of stable glycosides and glycoproteins. This biomimetic concept uses 'cap and glycosylate' technology to selectively activate and substitute the anomeric hydroxyl group in a native sugar, generating a temporary thioglycoside intermediate that unde...
Scientists at Scripps Research have developed a potential drug-like molecule that blocks the first stage of type A influenza infection. The inhibitors target hemagglutinin, a protein on the surface of type A influenza viruses, and have shown improved cellular antiviral potency compared to previous compounds.
Scientists have found an effective treatment for spitting cobra snakebites by blocking one of the major dermonecrosis-causing toxins with varespladib. The study suggests that this repurposed drug can prevent tissue damage and may become a valuable treatment against black-necked and red spitting cobra venoms.
Researchers have discovered a small molecule compound called ESI1 that can regenerate vital myelin coatings, potentially treating multiple sclerosis and age-related cognitive deficits. The treatment promotes healing by clearing a roadblock in the repair process, allowing oligodendrocytes to produce myelin sheaths.
Researchers at CeMM and Pfizer have developed a novel method to measure the binding activity of hundreds of small molecules against thousands of human proteins. The study revealed tens of thousands of ligand-protein interactions that can now be explored for drug development.
Researchers at UC Riverside demonstrate a new vaccine strategy targeting a common viral genome part, eliminating the need for annual booster shots. The vaccine uses small RNA molecules to boost the immune system, making it safe for babies and those with weakened immunity.
Researchers have created a method to make fully recyclable polymers from plant cellulose, which can replace some plastics and reduce plastic pollution. The new polymers have various structures that offer different applications, including high-performance materials for optical, electronic, and biomedical uses.
Researchers investigated the impact of senolytic treatments on DNA methylation clocks and epigenetic age. Results showed significant increases in epigenetic age acceleration with Dasatinib and Quercetin treatment, but not with Fisetin addition.
Scientists create 'μkiss' technique for precise delivery of materials to individual cells, offering new possibilities in single-cell science and next-generation therapeutic applications. The method provides full control over location, time, and scale of material application, enabling detailed studies of cellular processes.
Scientists at University of Utah and University of Massachusetts Amherst uncover the physics behind dopant-polymer interactions that explain inconsistent conductivity issues in organic materials. The discovery reveals that a critical mass of electrons triggers collective screening, allowing rest of electrons to flow unimpeded.
ATH-1105, a small molecule positive modulator of the neurotrophic HGF system, demonstrates significant neuroprotective effects and extends survival in preclinical models of ALS. The study highlights the therapeutic potential of ATH-1105 in slowing or stopping neurodegeneration.
The new method reveals critical information about how to target proteins with small molecules, identifying over a thousand new locks and corresponding keys. This breakthrough could lead to the development of more effective therapeutics for nearly any human disease.
A Philippine sea cucumber species has been found to contain diverse classes of valuable small molecules with potential biomedical applications. These bioactive compounds, including terpenoid glycosides and saponins, have reported anti-cancer benefits.
Researchers at the University of Pittsburgh have discovered a potential new target for treating Barth syndrome, a rare genetic disease with devastating consequences. They identified a molecular culprit that could be targeted to potentially reverse the disease course and developed a small-molecule drug candidate to correct genetic tafaz...
The study analyzed 170 known bacterial languages, grouping them into clusters based on molecular structure. Bacteria can understand related languages, but not those with vastly different languages. This understanding will aid in refining treatment approaches and developing biotechnology applications.